Labcorp Achieves IVDR CE-Marking for PGDx elio™ Tissue Complete, Expanding Access to Personalized Cancer Care Across the EU

Reuters

2025/07/29

Labcorp Achieves IVDR CE-Marking for PGDx elio™ Tissue Complete, Expanding Access to Personalized Cancer Care Across the EU

Labcorp Holdings Inc., a leading provider of comprehensive laboratory services, announced that its PGDx elio™ tissue complete has achieved IVDR CE-marking under the European Union's new In Vitro Diagnostic Regulation (IVDR). This marks it as the first and only test of its kind in the EU to be CE-marked for comprehensive solid tumor profiling. The approval is a significant milestone, expanding access to personalized cancer care for approximately 2.7 million cancer patients annually in the EU. The test's ability to analyze multiple biomarkers with limited tissue samples supports physicians in delivering guideline-based care and accelerates patient management plans. This achievement not only reflects Labcorp's commitment to advancing precision medicine but also provides biopharma partners with a reliable solution for clinical trial strategies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Labcorp Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DC39103) on July 29, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2555058979"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555058979\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555058979?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-29 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555058979","market":"fut","top_or_hot":-1,"title":"Labcorp Achieves IVDR CE-Marking for PGDx elio™ Tissue Complete, Expanding Access to Personalized Cancer Care Across the EU","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Labcorp Achieves IVDR CE-Marking for PGDx elio™ Tissue Complete, Expanding Access to Personalized Cancer Care Across the EU\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Labcorp Holdings Inc., a leading provider of comprehensive laboratory services, announced that its PGDx elio™ tissue complete has achieved IVDR CE-marking under the European Union's new In Vitro Diagnostic Regulation (IVDR). This marks it as the first and only test of its kind in the EU to be CE-marked for comprehensive solid tumor profiling. The approval is a significant milestone, expanding access to personalized cancer care for approximately 2.7 million cancer patients annually in the EU. The test's ability to analyze multiple biomarkers with limited tissue samples supports physicians in delivering guideline-based care and accelerates patient management plans. This achievement not only reflects Labcorp's commitment to advancing precision medicine but also provides biopharma partners with a reliable solution for clinical trial strategies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Labcorp Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DC39103) on July 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Labcorp Achieves IVDR CE-Marking for PGDx elio™ Tissue Complete, Expanding Access to Personalized Cancer Care Across the EU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLabcorp Achieves IVDR CE-Marking for PGDx elio™ Tissue Complete, Expanding Access to Personalized Cancer Care Across the EU\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-29 19:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Labcorp Achieves IVDR CE-Marking for PGDx elio™ Tissue Complete, Expanding Access to Personalized Cancer Care Across the EU\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Labcorp Holdings Inc., a leading provider of comprehensive laboratory services, announced that its PGDx elio™ tissue complete has achieved IVDR CE-marking under the European Union's new In Vitro Diagnostic Regulation (IVDR). This marks it as the first and only test of its kind in the EU to be CE-marked for comprehensive solid tumor profiling. The approval is a significant milestone, expanding access to personalized cancer care for approximately 2.7 million cancer patients annually in the EU. The test's ability to analyze multiple biomarkers with limited tissue samples supports physicians in delivering guideline-based care and accelerates patient management plans. This achievement not only reflects Labcorp's commitment to advancing precision medicine but also provides biopharma partners with a reliable solution for clinical trial strategies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Labcorp Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DC39103) on July 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健護理服務","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nNDL6bBsMn:1","article_id":"2555058979","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555058979","pubTimestamp":1753786965,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Labcorp Holdings Inc., a leading provider of comprehensive laboratory services, announced that its PGDx elio tissue complete has achieved IVDR CE-marking under the European Union's new In Vitro Diagnostic Regulation . This marks it as the first and only test of its kind in the EU to be CE-marked for comprehensive solid tumor profiling. The approval is a significant milestone, expanding access to personalized cancer care for approximately 2.7 million cancer patients annually in the EU. The test's ability to analyze multiple biomarkers with limited tissue samples supports physicians in delivering guideline-based care and accelerates patient management plans. This achievement not only reflects Labcorp's commitment to advancing precision medicine but also provides biopharma partners with a reliable solution for clinical trial strategies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","LU0742534661.SGD":"Fidelity America A-SGD (hedged)","BK4588":"碎股","BK4550":"红杉资本持仓","BK4585":"ETF&股票定投概念","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LH":"徕博科","LU0048573561.USD":"FIDELITY AMERICA \"A\" (USD) INC","LU0251142724.SGD":"Fidelity America A-SGD","LU0251131958.USD":"FIDELITY AMERICA \"A\" (USD) ACC","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC"},"translate_title":"Labcorp的PGDx elio获得IVDR CE标志™组织完整，扩大整个欧盟个性化癌症护理的可及性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LH":0.9},"content_text":"Labcorp Achieves IVDR CE-Marking for PGDx elio™ Tissue Complete, Expanding Access to Personalized Cancer Care Across the EU\n    \n\n        Labcorp Holdings Inc., a leading provider of comprehensive laboratory services, announced that its PGDx elio™ tissue complete has achieved IVDR CE-marking under the European Union's new In Vitro Diagnostic Regulation (IVDR). This marks it as the first and only test of its kind in the EU to be CE-marked for comprehensive solid tumor profiling. The approval is a significant milestone, expanding access to personalized cancer care for approximately 2.7 million cancer patients annually in the EU. The test's ability to analyze multiple biomarkers with limited tissue samples supports physicians in delivering guideline-based care and accelerates patient management plans. This achievement not only reflects Labcorp's commitment to advancing precision medicine but also provides biopharma partners with a reliable solution for clinical trial strategies.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Labcorp Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DC39103) on July 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}